EXEL

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Exelixis (EXEL), which belongs to the Zacks Medical - Biomedical and Genetics industry. This drug developer has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 19.04%. For the last reported quarter, Exelixis came out with earnings of $0.87 per share versus the Zacks Consensus Estimate of $0.75 per share, representing a surprise of 16.00%. For the previous quarter, the company was expected to post earnings of $0.77 per share and it actually produced earnings of $0.94 per share, delivering a surprise of 22.08%. Thanks in part to this history, there has been a favorable change in earnings estimates for Exelixis lately. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the stock is positive, which is a great indicator of an earnings beat, particularly when combined with its solid Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Exelixis currently has an Earnings ESP of +6.31%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #2 (Buy) indicates that another beat is possibly around the corner. With the Earnings ESP metric, it's important to note that a negative value reduces its predictive power; however, a negative Earnings ESP does not indicate an earnings miss. Many companies end up beating the consensus EPS estimate, but that may not be the sole basis for their stocks mov...

It has been about a month since the last earnings report for Halozyme Therapeutics (HALO). Shares have added about 0.8% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Halozyme Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Halozyme reported first-quarter 2026 adjusted earnings of $1.60 per share, which beat the Zacks Consensus Estimate of $1.54. Earnings rose 44.1% year over year. Total revenues in the first quarter increased 42% year over year to $376.7 million. Revenues too surpassed the Zacks Consensus Estimate of $358 million. The top-line growth was primarily driven by an increase in product sales as well as higher royalty payments. Halozyme received royalty payments from Roche for Phesgo and J&J for subcutaneous Darzalex, as well as argenx for Vyvgart Hytrulo. Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements. Royalty revenues totaled $240.7 million in the first quarter, up 43% from the year-ago quarter’s level. This was mainly due to the robust demand for Phesgo, subcutaneous Darzalex and Vyvgart Hytrulo, on which it earns royalties. Royalty revenues, however, missed our model estimate of $256.6 million. Product sales were $130.4 million in the first quarter, up 67.2% from the year-ago quarter’s level. Halozyme has two commercial proprietary products, Hylenex and Xyosted, with the latter acquired from Antares Pharma in 2022. Product sales beat our model estimate of $91.1 million. Revenues under collaborative agreements were $5.6 million in the reported quarter, down almost 70% year over year. Adjusted EBITDA was $229.5 million in the reported quarter, compared with $162 million in the year-ago quarter. Halozyme had cash, cash equivalents and marketable securities of $320.9 million as of March 31, 2026, compared with $145.4 million as of Dec. 31, 2025. Halozyme reiterated its total revenue guidance for 2026, which it had provided earlier this year. The company continues to expect total revenues in the range of $1.71 billion to $1.81 billion for 2026, implying year-over-year growth of 22% to 30%. Total revenues...

It has been about a month since the last earnings report for Exelixis (EXEL). Shares have added about 6% in that time frame, outperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Exelixis due for a pullback? Well, first let's take a quick look at its latest earnings report in order to get a better handle on the recent drivers for Exelixis, Inc. before we dive into how investors and analysts have reacted as of late. EXEL Q1 Earnings Top Estimates, Colorectal Cancer Drug in Focus Exelixis reported mixed results for the first quarter of 2026. Adjusted earnings per share (EPS) of 87 cents comfortably beat the Zacks Consensus Estimate of 75 cents. The company posted adjusted EPS of 62 cents in the year-ago quarter. Adjusted earnings exclude the impact of stock-based compensation expenses. Including stock-based compensation expense, EPS was 79 cents compared with 55 cents in the year-ago period. The bottom-line growth benefited from lower operating expenses and a decrease in shares outstanding due to ongoing buybacks. Net revenues of $611 million missed the Zacks Consensus Estimate of $613 million. The top line was up 10% year over year. EXEL’s Q1 Results in Detail Net product revenues of $555.0 million were up from $513.3 million in the year-ago quarter. Management attributed the increase to higher sales volume. Cabometyx (cabozantinib) generated revenues of $552.8 million, which missed the Zacks Consensus Estimate of $558 million and our model estimate of $564 million. The drug is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma. In March 2025, Exelixis obtained FDA approval for the label expansion of Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors (pNET). The drug was also approved for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET). Cometriq (cabozantinib capsules) generated $2.2 million in net product revenues for treating medullary thyroid cancer. Collaboration revenues, comprising license and collaboration servi...

– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo – ALAMEDA, Calif., May 30, 2026--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal trial, which showed that CABOMETYX® (cabozantinib) provided significant improvements in progression-free survival (PFS) versus placebo in patients with previously treated advanced neuroendocrine tumors (NET) regardless of functional status. These data will be presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting to be held from May 29 – June 2 in Chicago. "Understanding the effects of oral pathway inhibitors in patients with both functional and non-functional NET is critical in informing appropriate treatment-sequencing decisions," said Nikolaos A. Trikalinos, M.D., Associate Professor of Medicine, Washington University School of Medicine and Siteman Cancer Center. "Patients with hormone-producing tumors may require approaches that not only control tumor growth but also help mitigate challenging hormone-related symptoms. It is encouraging that our results reinforce cabozantinib as a meaningful treatment option for patients with advanced NET regardless of functional status. In both non-functional and functional NET, cabozantinib delivered substantial improvements in disease control compared to placebo, with median progression-free survival increasing threefold in non-functional NET and more than doubling in functional NET compared to placebo." In the phase 3 CABINET study, patients with locally advanced or metastatic pancreatic NET (pNET) or extra-pancreatic NET (epNET) were randomized 2:1 in separate cohorts to receive CABOMETYX 60 mg daily versus placebo. Of the 298 patients enrolled in both cohorts, 179 had non-functional NET (cabozantinib, n=123; placebo, n=56), 74 had functional (i.e., hormone-releasing) NET (cabozantinib, n=47; placebo, n=27); and 45 had unknown functional status (cabozantinib, n=28; placebo, n=17). These subgroup results presented today at ASCO 2026 show cabozantinib demonstrated improvements in PFS regardless of functional status. In patients with non-functional NET, the hazard ratio (HR) was 0.26 (95% confidence interval [CI]: 0.17–0.41; p<0.001); median PFS was 9.4 months...

The stock market rose to fresh highs Thursday on a reported interim U.S.-Iran deal. Dell soared overnight on earnings.

Exelixis, Inc. has already reported first-quarter 2026 results, with revenue rising to US$610.81 million and net income to US$210.47 million, alongside higher earnings per share versus a year earlier. Alongside these results, Exelixis completed a prior share repurchase authorization and launched a new US$750 million buyback while advancing its cabozantinib and zanzalintinib oncology franchises. We’ll now explore how Exelixis’ stronger quarterly earnings and continued cabozantinib growth might shape the company’s broader investment narrative. Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research. To own Exelixis, I think you need to believe that cabozantinib can remain a cash-generating oncology backbone while zanzalintinib matures into a second meaningful franchise. The stronger first quarter and higher cabozantinib revenue support that thesis but do not remove the key near term risk of continued gross to net pressure from discounted channels like 340B. The most important catalyst still sits with pipeline execution and regulatory outcomes for zanzalintinib across colorectal and renal indications. Among the recent announcements, the new US$750 million share repurchase program stands out alongside the earnings beat. The buyback, coming right after Exelixis completed a prior US$590.59 million authorization, matters because it is being layered onto a business still heavily reliant on cabozantinib while management pushes zanzalintinib through pivotal trials. How the company balances capital returns with funding late stage development will interact directly with those pipeline catalysts. Yet beneath the stronger quarter, investors should be aware of how rising 340B volume and potential pricing pressure could eventually... Read the full narrative on Exelixis (it's free!) Exelixis' narrative projects $3.3 billion revenue and $1.1 billion earnings by 2029. Uncover how Exelixis' forecasts yield a $47.53 fair value, in line with its current price. Some of the most optimistic analysts were previously modeling Exelixis to reach about US$3.8 billion in revenue and US$1.8 billion in earnings, which is a far more upbeat view than the baseline narrative that emphasizes cabozantinib concentration and 340B pressure. After this qu...

Exelixis, Inc. EXEL reported mixed results for the first quarter of 2026. Adjusted earnings per share (EPS) of 87 cents comfortably beat the Zacks Consensus Estimate of 75 cents. The company posted adjusted EPS of 62 cents in the year-ago quarter. Adjusted earnings exclude the impact of stock-based compensation expenses. Including stock-based compensation expense, EPS was 79 cents compared with 55 cents in the year-ago period. The bottom-line growth benefited from lower operating expenses and a decrease in shares outstanding due to ongoing buybacks. Net revenues of $611 million missed the Zacks Consensus Estimate of $613 million. The top line was up 10% year over year. The stock is up in pre-market trading in response to the first-quarter results. Year to date, Exelixis’ shares have risen 1.3% against the industry’s decline of 2.4%. Image Source: Zacks Investment Research Net product revenues of $555.0 million were up from $513.3 million in the year-ago quarter. Management attributed the increase to higher sales volume. Cabometyx (cabozantinib) generated revenues of $552.8 million, which missed the Zacks Consensus Estimate of $558 million and our model estimate of $564 million. The drug is approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma. In March 2025, Exelixis obtained FDA approval for the label expansion of Cabometyx for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic neuroendocrine tumors (pNET). The drug was also approved for adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated extra-pancreatic NET (epNET). Cometriq (cabozantinib capsules) generated $2.2 million in net product revenues for treating medullary thyroid cancer. Collaboration revenues, comprising license and collaboration services revenues, totaled $55.8 million, up 32.4% year over year. The improvement reflected higher royalty revenues from ex-U.S. cabozantinib sales generated by Ipsen and higher milestone-related revenues recognized during the period. Research and development expenses amounted to $199.9 million, down from $212.2 million in the prior-year quarter due to lower clinical trial and manufacturing...

Exelixis (EXEL) came out with quarterly earnings of $0.87 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.62 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +15.55%. A quarter ago, it was expected that this drug developer would post earnings of $0.77 per share when it actually produced earnings of $0.94, delivering a surprise of +22.08%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Exelixis, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $610.81 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 0.29%. This compares to year-ago revenues of $555.45 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Exelixis shares have added about 0.8% since the beginning of the year versus the S&P 500's gain of 5.2%. While Exelixis has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Exelixis was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Bu...

CABOMETYX commercial momentum accelerated in Q1 with record new patient starts, TRx share rising from 44% to 47% year‑over‑year and an expanded GI sales force to support a potential zanzalitinib colorectal cancer launch. Exelixis reported approximately $611 million in Q1 revenue (cabozantinib franchise net product revenues ~$555 million), ended the quarter with ~$1.4 billion in cash and marketable securities, repurchased ~$430.8 million of stock, and authorized a new $750 million buyback program. The zanzalitinib NDA for third‑line‑plus CRC is under FDA review with a PDUFA in early December after STELLAR‑303 showed a 20% reduction in risk of death in the ITT population, and multiple pivotal trials across CRC, RCC, NETs and other indications are advancing. Interested in Exelixis, Inc.? Here are five stocks we like better. Exelixis Reports Solid Earnings—Are New Highs Back on the Table? Exelixis (NASDAQ:EXEL) executives highlighted continued momentum for its cabozantinib franchise and provided updates on the expanding development program for zanzalitinib during the company’s first-quarter 2026 earnings call. President and CEO Mike Morrissey said the company is “off to a strong start in 2026,” pointing to “continued strong performance of the cabozantinib business” and progress toward building a multi-franchise oncology company focused on genitourinary (GU) and gastrointestinal (GI) cancers. → Roblox Stock Slides to New Low as Safety Changes Weigh on Outlook 3 Stocks to Buy for a Soft Landing, If There Is One Morrissey said CABOMETYX continued to grow in “revenue, demand, and market share” and described it as the leading tyrosine kinase inhibitor (TKI) for renal cell carcinoma (RCC) and the market leader in oral second-line-plus neuroendocrine tumors (NETs). He also said Exelixis expedited the build-out of its GI sales team during the quarter to “accelerate the growth of the CABOMETYX net opportunity” ahead of a potential zanzalitinib colorectal cancer (CRC) launch later in 2026. EVP of Commercial P.J. Haley said the first quarter delivered the “highest number of new patient starts in a quarter ever for CABOMETYX.” He added that CABOMETYX plus nivolumab posted its highest quarterly first-line RCC market share to date. Haley also cited prescription trends across an oral TKI “market basket” (cabozantinib, lenvatinib, axitinib, sunitinib, and pazopanib), saying CAB...

ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Exelixis Inc. (EXEL) on Tuesday reported first-quarter earnings of $210.5 million. The Alameda, California-based company said it had net income of 79 cents per share. Earnings, adjusted for stock option expense, came to 87 cents per share. The results exceeded Wall Street expectations. The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 75 cents per share. The drug developer posted revenue of $610.8 million in the period, falling short of Street forecasts. Seven analysts surveyed by Zacks expected $612.6 million. Exelixis expects full-year revenue in the range of $2.53 billion to $2.63 billion. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EXEL at https://www.zacks.com/ap/EXEL

Exelixis (EXEL) reported Q1 non-GAAP net income late Tuesday of $0.87 per diluted share, up from $0.

Exelixis (EXEL) reported $610.81 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 10%. EPS of $0.87 for the same period compares to $0.62 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $612.57 million, representing a surprise of -0.29%. The company delivered an EPS surprise of +15.55%, with the consensus EPS estimate being $0.75. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Exelixis performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Collaboration revenues: $55.84 million compared to the $49.26 million average estimate based on seven analysts. The reported number represents a change of -17769.3% year over year. Revenues- Net product revenues: $554.98 million versus the seven-analyst average estimate of $563.31 million. The reported number represents a year-over-year change of +8.1%. Revenues- Net product revenues- COMETRIQ: $2.2 million versus the six-analyst average estimate of $2.51 million. The reported number represents a year-over-year change of -8.8%. Revenues- Net product revenues- CABOMETYX: $552.8 million versus $558.02 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a +8.2% change. View all Key Company Metrics for Exelixis here>>> Shares of Exelixis have returned +0.4% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Exelixis, Inc. (EXEL) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research